Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma

The Journal of Clinical Oncology has published a trial of a response-adapted regimen combining mosunetuzumab (a bispecific antibody binding CD20 and CD3) with polatuzumab vedotin and obinutuzumab in previously untreated indolent B-cell lymphoma. The regimen is chemotherapy-free, given as first-line treatment, with treatment intensity adjusted according to early response assessment. The publisher releases only the bibliographic record (volume 44, issue 27, pages 2625–2633) and no results abstract, so this summary gives neither the number of patients treated, nor response rates, nor follow-up duration; those data are in the full text, which the link points to.